SGLT2 inhibitors for prevention and treatment diabetic kidney disease:a network meta-analysis of randomised controlled trials

Published: 1 July 2021| Version 1 | DOI: 10.17632/93557j3rmv.1
Contributor:
li fang

Description

The data were the results of composite kidney outcomes and urinary albumin to creatinine ratio in patients with type 2 diabetes after taking SGLT2 inhibitors or placebo.

Files

Categories

Diabetic Nephropathy

Licence